The compensatory activation of the MAPK pathway in response to PI3K/AKT inhibitors has been noted in CCA, indicating that simultaneous inhibition of both pathways may surmount resistance and improve therapeutic success. The gene discussed is AKT1; the disease is cholangiocarcinoma.